DOCSLIB.ORG

PCT Gazette, Weekly Issue No. 13, 2004

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PCT Gazette, Weekly Issue No. 13, 2004 13/2004 25 Mar/mar 2004 PCT Gazette - Section III - Gazette du PCT 7007 SECTION III WEEKLY INDEXES INDEX HEBDOMADAIRES INTERNATIONAL APPLICATION NUMBERS AND CORRESPONDING INTERNATIONAL PUBLICATION NUMBERS NUMÉROS DES DEMANDES INTERNATIONALES ET NUMÉROS DE PUBLICATION INTERNATIONALE CORRESPONDANTS International International International International International International Application Publication Application Publication Application Publication Numbers Numbers Numbers Numbers Numbers Numbers Numéros des Numéros de Numéros des Numéros de Numéros des Numéros de demandes publication demandes publication demandes publication internationales internationale internationales internationale internationales internationale AT BR CN PCT/AT2003/000079 WO 2004/025168 PCT/BR2003/000128 WO 2004/024058 PCT/CN2002/000705 WO 2004/025192 PCT/AT2003/000258 WO 2004/025667 PCT/CN2002/000801 WO 2004/024847 PCT/AT2003/000259 WO 2004/023943 CA PCT/CN2002/000879 WO 2004/025180 PCT/AT2003/000263 WO 2004/024605 PCT/CA2002/001381 WO 2004/024962 PCT/CN2003/000109 WO 2004/025932 PCT/AT2003/000265 WO 2004/023919 PCT/CA2002/001393 WO 2004/024545 PCT/CN2003/000198 WO 2004/025681 PCT/AT2003/000266 WO 2004/025573 PCT/CA2003/000362 WO 2004/024553 PCT/CN2003/000252 WO 2004/025605 PCT/AT2003/000267 WO 2004/025574 PCT/CA2003/001152 WO 2004/024412 PCT/CN2003/000278 WO 2004/025064 PCT/AT2003/000271 WO 2004/024020 PCT/CA2003/001187 WO 2004/024574 PCT/CN2003/000500 WO 2004/024724 PCT/AT2003/000272 WO 2004/024529 PCT/CA2003/001290 WO 2004/024419 PCT/CN2003/000502 WO 2004/024678 PCT/AT2003/000273 WO 2004/024361 PCT/CA2003/001294 WO 2004/025443 PCT/CN2003/000503 WO 2004/024680 PCT/CA2003/001321 WO 2004/025524 PCT/CN2003/000524 WO 2004/025899 AU PCT/CA2003/001326 WO 2004/025459 PCT/CN2003/000706 WO 2004/025198 PCT/AU2003/000624 WO 2004/025081 PCT/CA2003/001327 WO 2004/025117 PCT/CN2003/000745 WO 2004/025035 PCT/AU2003/000833 WO 2004/025484 PCT/CA2003/001328 WO 2004/025815 PCT/CN2003/000765 WO 2004/024905 PCT/AU2003/001014 WO 2004/024463 PCT/CA2003/001331 WO 2004/024709 PCT/CN2003/000766 WO 2004/025031 PCT/AU2003/001098 WO 2004/025626 PCT/CA2003/001332 WO 2004/023903 PCT/CN2003/000769 WO 2004/023945 PCT/AU2003/001156 WO 2004/025112 PCT/CA2003/001333 WO 2004/025460 PCT/CN2003/000770 WO 2004/025981 PCT/AU2003/001167 WO 2004/023914 PCT/CA2003/001337 WO 2004/024289 PCT/CN2003/000776 WO 2004/024181 PCT/AU2003/001169 WO 2004/025988 PCT/CA2003/001343 WO 2004/024131 PCT/CN2003/000779 WO 2004/025872 PCT/AU2003/001174 WO 2004/024405 PCT/CA2003/001367 WO 2004/025999 PCT/CN2003/000780 WO 2004/024146 PCT/AU2003/001180 WO 2004/024409 PCT/CA2003/001372 WO 2004/023991 PCT/AU2003/001181 WO 2004/024584 PCT/CA2003/001374 WO 2004/025750 DE PCT/AU2003/001182 WO 2004/023987 PCT/CA2003/001377 WO 2004/025525 PCT/DE2003/001895 WO 2004/025238 PCT/AU2003/001183 WO 2004/024342 PCT/CA2003/001378 WO 2004/025761 PCT/DE2003/002001 WO 2004/024301 PCT/AU2003/001184 WO 2004/023904 PCT/CA2003/001379 WO 2004/025904 PCT/DE2003/002006 WO 2004/025322 PCT/AU2003/001186 WO 2004/025660 PCT/CA2003/001383 WO 2004/026000 PCT/DE2003/002007 WO 2004/025061 PCT/AU2003/001188 WO 2004/024246 PCT/CA2003/001386 WO 2004/025500 PCT/DE2003/002102 WO 2004/025090 PCT/AU2003/001191 WO 2004/024242 PCT/CA2003/001393 WO 2004/024759 PCT/DE2003/002129 WO 2004/025114 PCT/AU2003/001193 WO 2004/025653 PCT/CA2003/001395 WO 2004/024355 PCT/DE2003/002260 WO 2004/025105 PCT/AU2003/001194 WO 2004/025052 PCT/CA2003/001397 WO 2004/024906 PCT/DE2003/002335 WO 2004/024517 PCT/AU2003/001195 WO 2004/025608 PCT/CA2003/001398 WO 2004/024908 PCT/DE2003/002344 WO 2004/024676 PCT/AU2003/001197 WO 2004/025173 PCT/CA2003/001402 WO 2004/025110 PCT/DE2003/002353 WO 2004/025855 PCT/AU2003/001200 WO 2004/024915 PCT/CA2003/001405 WO 2004/024201 PCT/DE2003/002405 WO 2004/024498 PCT/AU2003/001201 WO 2004/024758 PCT/CA2003/001406 WO 2004/024546 PCT/DE2003/002561 WO 2004/025875 PCT/AU2003/001202 WO 2004/024947 PCT/CA2003/001407 WO 2004/024123 PCT/DE2003/002572 WO 2004/025328 PCT/AU2003/001203 WO 2004/025689 PCT/CA2003/001408 WO 2004/024171 PCT/DE2003/002574 WO 2004/025725 PCT/AU2003/001209 WO 2004/024773 PCT/DE2003/002576 WO 2004/025731 PCT/AU2003/001210 WO 2004/024334 CH PCT/DE2003/002584 WO 2004/025987 PCT/AU2003/001211 WO 2004/025188 PCT/CH2002/000497 WO 2004/025742 PCT/DE2003/002597 WO 2004/024449 PCT/AU2003/001212 WO 2004/024902 PCT/CH2002/000558 WO 2004/024257 PCT/DE2003/002598 WO 2004/024448 PCT/AU2003/001213 WO 2004/024557 PCT/CH2003/000385 WO 2004/025235 PCT/DE2003/002603 WO 2004/025763 PCT/AU2003/001214 WO 2004/023871 PCT/CH2003/000576 WO 2004/025579 PCT/DE2003/002679 WO 2004/025882 PCT/CH2003/000578 WO 2004/024413 PCT/DE2003/002680 WO 2004/025856 BE PCT/CH2003/000593 WO 2004/024418 PCT/DE2003/002681 WO 2004/025857 PCT/BE2002/000145 WO 2004/024556 PCT/CH2003/000603 WO 2004/025039 PCT/DE2003/002694 WO 2004/024451 PCT/BE2003/000148 WO 2004/024560 PCT/CH2003/000607 WO 2004/025189 PCT/DE2003/002698 WO 2004/025968 PCT/BE2003/000149 WO 2004/024959 PCT/CH2003/000611 WO 2004/023944 PCT/DE2003/002710 WO 2004/024511 PCT/BE2003/000150 WO 2004/024549 PCT/CH2003/000615 WO 2004/024152 PCT/DE2003/002717 WO 2004/025919 PCT/BE2003/000151 WO 2004/024286 PCT/CH2003/000616 WO 2004/023890 PCT/DE2003/002726 WO 2004/025124 PCT/BE2003/000152 WO 2004/023879 PCT/CH2003/000620 WO 2004/024426 PCT/DE2003/002728 WO 2004/025796 PCT/CH2003/000621 WO 2004/024424 PCT/DE2003/002729 WO 2004/025341 BG PCT/CH2003/000626 WO 2004/025526 PCT/DE2003/002740 WO 2004/025739 PCT/BG2002/000030 WO 2004/025610 PCT/DE2003/002741 WO 2004/025729 CN PCT/DE2003/002750 WO 2004/024457 BR PCT/CN2002/000638 WO 2004/025448 PCT/DE2003/002752 WO 2004/025678 PCT/BR2003/000093 WO 2004/025120 PCT/CN2002/000657 WO 2004/025629 PCT/DE2003/002761 WO 2004/024490 PCT/BR2003/000127 WO 2004/024469 PCT/CN2002/000688 WO 2004/025455 PCT/DE2003/002766 WO 2004/024115 13/2004 7008 PCT Gazette - Section III - Gazette du PCT 25 Mar/mar 2004 International Application Numbers and Corresponding International Publication Numbers (Continued) Numéros des demandes internationales et numéros de publication internationale correspondants (Suite) International International International International International International Application Publication Application Publication Application Publication Numbers Numbers Numbers Numbers Numbers Numbers Numéros des Numéros de Numéros des Numéros de Numéros des Numéros de demandes publication demandes publication demandes publication internationales internationale internationales internationale internationales internationale DE EP EP PCT/DE2003/002772 WO 2004/025493 PCT/EP2002/010286 WO 2004/025794 PCT/EP2003/009163 WO 2004/025196 PCT/DE2003/002775 WO 2004/025924 PCT/EP2002/010400 WO 2004/025895 PCT/EP2003/009172 WO 2004/023968 PCT/DE2003/002778 WO 2004/024358 PCT/EP2002/011355 WO 2004/025778 PCT/EP2003/009179 WO 2004/025520 PCT/DE2003/002782 WO 2004/025104 PCT/EP2002/011916 WO 2004/024849 PCT/EP2003/009188 WO 2004/025187 PCT/DE2003/002814 WO 2004/025858 PCT/EP2003/006065 WO 2004/025960 PCT/EP2003/009196 WO 2004/025382 PCT/DE2003/002815 WO 2004/025918 PCT/EP2003/006115 WO 2004/025570 PCT/EP2003/009205 WO 2004/025060 PCT/DE2003/002818 WO 2004/025111 PCT/EP2003/007066 WO 2004/024148 PCT/EP2003/009206 WO 2004/024596 PCT/DE2003/002830 WO 2004/024380 PCT/EP2003/007067 WO 2004/024162 PCT/EP2003/009210 WO 2004/024621 PCT/DE2003/002836 WO 2004/024948 PCT/EP2003/007348 WO 2004/024364 PCT/EP2003/009213 WO 2004/025143 PCT/DE2003/002849 WO 2004/025916 PCT/EP2003/007439 WO 2004/024199 PCT/EP2003/009222 WO 2004/025183 PCT/DE2003/002851 WO 2004/025163 PCT/EP2003/007564 WO 2004/025323 PCT/EP2003/009237 WO 2004/025543 PCT/DE2003/002862 WO 2004/024397 PCT/EP2003/007583 WO 2004/024805 PCT/EP2003/009240 WO 2004/025185 PCT/DE2003/002863 WO 2004/024450 PCT/EP2003/007856 WO 2004/025722 PCT/EP2003/009242 WO 2004/023969 PCT/DE2003/002877 WO 2004/025142 PCT/EP2003/007917 WO 2004/025349 PCT/EP2003/009248 WO 2004/024176 PCT/DE2003/002878 WO 2004/025294 PCT/EP2003/008126 WO 2004/026013 PCT/EP2003/009249 WO 2004/024109 PCT/DE2003/002880 WO 2004/025369 PCT/EP2003/008210 WO 2004/025920 PCT/EP2003/009250 WO 2004/024737 PCT/DE2003/002881 WO 2004/024848 PCT/EP2003/008265 WO 2004/025285 PCT/EP2003/009251 WO 2004/024663 PCT/DE2003/002895 WO 2004/024234 PCT/EP2003/008324 WO 2004/025793 PCT/EP2003/009252 WO 2004/024738 PCT/DE2003/002897 WO 2004/024306 PCT/EP2003/008408 WO 2004/024806 PCT/EP2003/009253 WO 2004/025370 PCT/DE2003/002902 WO 2004/024299 PCT/EP2003/008578 WO 2004/024101 PCT/EP2003/009255 WO 2004/024839 PCT/DE2003/002903 WO 2004/025092 PCT/EP2003/008593 WO 2004/024785 PCT/EP2003/009257 WO 2004/024422 PCT/DE2003/002905 WO 2004/025791 PCT/EP2003/008660 WO 2004/025597 PCT/EP2003/009261 WO 2004/025383 PCT/DE2003/002910 WO 2004/024489 PCT/EP2003/008688 WO 2004/024659 PCT/EP2003/009267 WO 2004/024837 PCT/DE2003/002911 WO 2004/025127 PCT/EP2003/008737 WO 2004/024661 PCT/EP2003/009273 WO 2004/025011 PCT/DE2003/002912 WO 2004/024524 PCT/EP2003/008769 WO 2004/023928 PCT/EP2003/009278 WO 2004/023927 PCT/DE2003/002913 WO 2004/025144 PCT/EP2003/008793 WO 2004/024105 PCT/EP2003/009283 WO 2004/024427 PCT/DE2003/002921 WO 2004/024479 PCT/EP2003/008808 WO 2004/025337 PCT/EP2003/009284 WO 2004/024420 PCT/DE2003/002925 WO 2004/025043 PCT/EP2003/008809 WO 2004/024107 PCT/EP2003/009285 WO 2004/025335 PCT/DE2003/002926 WO 2004/024824 PCT/EP2003/008815 WO 2004/024544 PCT/EP2003/009287 WO 2004/025353 PCT/DE2003/002927 WO 2004/024385 PCT/EP2003/008816 WO 2004/024539 PCT/EP2003/009299 WO 2004/025299 PCT/DE2003/002928 WO 2004/025145 PCT/EP2003/008817
Load more

Recommended publications
  • Preven Ng Pharmaceu Cal Pollu on and Diversion
    Preven&ng Pharmaceu&cal Pollu&on and Diversion Kate Hagemann & Sierra Fletcher Product Stewardship Ins&tute How to Participate Today • Open and close your Panel • View, Select, and Test your audio • Submit text questions • Raise your hand • Q&A addressed at the end of today’s session • Everyone will receive an email within 24 hours with a link to view a recorded version of today’s session Who is the Product Stewardship Instute? § Non-profit founded in 2000 § Membership ü 47 States ü 200+ Local governments ü 70+ Corporate, Organizaonal, Academic & Non-U.S. Government Partners § Board of Directors: 7 states, 4 local agencies • Mul4-stakeholder product stewardship network 3 The Problem: Waste Pharmaceucals 1. Environmental Concerns 2. Drug Diversion concerns 3. Public Safety Concerns 4 1. Environmental Concerns • Effects in the environment: – Endocrine disruptors – An&bio&c resistance • Pharmaceu&cals enter the environment via a number of channels – Agricultural run-off – Human excre&on – Improper disposal • Current waste water treatment plants cannot remove pharmaceu&cal compounds April 15, 2011 5 Evidence of pharmaceucals In our waterways • Minnesota Pollu&on Control Agency (2011) • USGS (June 2002) •“a broad range of chemicals found in residen3al, industrial, and agricultural wastewaters commonly occurs in mixtures at low concentra3ons downstream from areas of intense urbaniza3on and animal producon. The chemicals include human and veterinary drugs (including an3bio3cs), natural and synthe3c hormones, detergent metabolites, plas3cizers, inseccides, and fire retardants. One or more of these chemicals were found in 80 percent of the streams sampled” April 15, 2011 6 Environmental Impacts • Ecological impacts remain unknown • Observed impacts: – Abnormali&es – Disrupts reproduc&ve systems/risk of ex&ncon • Baylor University researchers found residues human medicaons in fish.
    [Show full text]
  • 38Th Annual Conference
    38th Annual Conference Conference Program Book Sponsored by: November 5-8, 2019 Booth #232 Salt Lake City, Utah Salt Palace Convention Center REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Committed to Patients Powered by Science Driven by Experience Amelia, CLN2 Jason, MPS II Charlie, HoFH Christopher, MPS I Geri, Wet AMD Our investigational gene therapy product candidates are designed to deliver genes to cells to address the genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. • 4 clinical stage programs in retinal, metabolic, and neurodegenerative diseases • Proprietary NAV® Technology Platform includes exclusive worldwide rights to over 100 AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 REGENXBIO.com Welcome to Salt Lake City! n behalf of the National Society of Genetic Counselors (NSGC), the Annual Conference Program Committee and the NSGC Board of O Directors, thank you for joining us! Table of Contents NSGC is excited to bring you education and networking opportunities Conference Information 5 designed to help you elevate the field of genetic counseling. Educational Schedule-at-a-Glance 8 sessions will cover a variety of topics at the forefront of genomics, such as gene editing, polygenic risk scores and artificial intelligence. Convention Center Map 13 Educational highlights you do not want to miss include: 40 years of the Reunion Information 14 Genetic Counseling Profession: A Foundation for the Future, The NSGC and ASHG Joint Session: Genetic Counselors in Research: From Dabbling Session Speakers + Objectives 16 in Clinic to an NIH Grant and the Professional Issues Panel.
    [Show full text]
  • Appendix 2 PCPSA Members Page 1 of 3 Companies Registered with PCPSA in 2008 Page: 2
    Companies registered with PCPSA in 2008 Page: 1 Company PCPSA Categories Registration Date AbbottTotals Laboratories Limited Brand Name November 8, 2006 Abraxis BioScience Inc. Generic December 4, 2006 Actelion Pharmaceuticals Canada Inc. Brand Name April 22, 2005 Advantage CKN Self-care June 22, 2001 Alcon Canada Inc. Brand Name March 7, 2007 Amgen Canada Inc. Brand Name March 9, 2007 Apotex Inc. Generic September 16, 2002 Astellas Pharma Canada Inc. Brand Name November 10, 2006 AstraZeneca Canada Inc. Brand Name December 14, 2001 Au Naturel Canada Inc. Self-care November 14, 2007 Axcan Pharma Inc. Brand Name April 6, 2005 Bayer Inc. Brand Name, Self-care February 5, 2004 Bioforce Canada Inc. Self-care August 27, 2007 Biovail Pharmaceuticals Canada Brand Name Boehringer Ingelheim Canada Ltd. Brand Name, Self-care July 21, 2004 Boiron Canada Inc. Self-care May 9, 2007 Bristol-Myers Squibb Pharmaceutical Group Brand Name, Self-care Canada Safeway Ltd. Self-care November 5, 2007 Chattem (Canada) Inc. Self-care April 23, 2004 Church & Dwight Canada Self-care August 14, 2001 Cobalt Pharmaceuticals Inc. Generic November 15, 2006 Combe Incorporated Self-care December 5, 2006 Costco Self-care CV Technologies Inc. Self-care October 26, 2006 Cytex Pharmaceutical Inc. Generic July 30, 2007 Eli Lilly Canada Inc. Brand Name September 9, 2001 EMD-Serono Canada Inc. Brand Name October 1, 2008 Enzymatic Therapy Self-care Ferring Inc. Brand Name Gaia Garden Herbals Inc. Self-care Galderma Canada Brand Name September 14, 2004 General Nutrition Centres Canada Self-care March 20, 2008 GenPharm Inc. Generic GlaxoSmithKline Consumer Healthcare Self-care August 30, 2001 GlaxoSmithKline Inc.
    [Show full text]
  • Product Stewardship Financing Models: a Look at the Post-Consumer Product Stewardship Association
    Product Stewardship Financing Models: A Look at the Post-Consumer Product Stewardship Association Type of Brand-owner funded take-back program (mandatory in BC and Manitoba). Program: Pharmaceuticals and natural health products, including prescription drugs, nonprescription Scope: medicines and natural health products such as herbal products, mineral and vitamin supplements (accepted in household quantities). In 1997, the B.C. Waste Management Act – Post Consumer Residual Stewardship, required all Status: brand-owners of pharmaceutical products to be responsible for their products’ end-of-life disposal. Starting in 2000, PCPSA began managing the stewardship plan with the Medications Return Program. The Recycling Regulation (B.C. Reg 449/2004) has now replaced the previous regulation. Overview Unused medications are a health and safety hazard when stored in patients’ homes. They can also damage the natural environment when incorrectly used or disposed of. The Post-Consumer Pharmaceutical Stewardship Association (PCPSA) is a non-profit organization that directly administers the Medications Return Program through funding from pharmaceutical and consumer health products members. PCPSA was established by the industry to comply with British Columbia’s Waste Management Act, a law intended to reduce the environmental and public health risks associated with consumer goods, including leftover medications. The act requires producers to establish a system to safely collect and dispose of the public’s unused medications. PCPSA has been successfully administering the program since 2000 and now represents over 140 pharmaceutical and consumer health products brand-owners (see the final page for a full listing). While these programs are regulated in British Columbia and Manitoba similar programs are run on a voluntary basis in other provinces and territories The program has been extremely successful in gaining the support and participation of community pharmacies.
    [Show full text]
  • Appendix B - Product Name Sorted by Applicant
    JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
    [Show full text]
  • Pharmaceuticals and Product Stewardship
    Pharmaceuticals and Product Stewardship Sierra Fletcher Product Stewardship Institute April 29, 2011 Who is the Product Stewardship Institute? . Non‐profit founded in 2000 . Membership 47 States 200+ Local governments 70+ Corporate, Organizational, Academic & Non‐U.S. Government Partners . Board of Directors: 7 states, 4 local agencies • Multi‐stakeholder product stewardship network April 29, 2011 2 Product Stewardship : councils & other groups promoting product stewardship April 29, 2011 3 Why do we need it? The average American throws away 1,600 pounds of trash each year That means by age 25 you’ve thrown away 40,000 pounds Different Kinds of Toxicity April 29, 2011 5 We are all responsible… Shared Responsibility Manufacturers Retailers Other Businesses Government Consumers April 29, 2011 6 PSI Principles of Product Stewardship 1. Cost internalization 2. Shared responsibility (manufacturers have greatest role) 3. Lifecycle costs 4. Performance goals 5. Flexibility for producers o Basic building blocks of product stewardship programs o Developed by PSI in 2001 o Endorsements: National League of Cities, Environmental Council of States, Solid Waste Association of North America, and many other organizations April 29, 2011 7 Examples of Product Stewardship • Government oversees the implementation of product stewardship laws. • Phone book industry offers the public the chance to opt‐out of receiving phone books. • Manufacturer removes toxic substance from product or manufacturing process. • Retailers collect products for recycling. • Rechargeable battery manufacturers provide collection boxes to recycle their product.* • Fluorescent lamp manufacturers implement recycling program in Maine.* April 29, 2011 8 Extended producer responsibility Extended Producer Responsibility (EPR), a central tenet of product stewardship, is a policy approach in which the producer’s responsibility for their product extends to the post‐consumer management of that product and its packaging.
    [Show full text]
  • Associate Member Companies As of October 15, 2012 A&D Medical
    Associate Member Companies as of October 15, 2012 A&D Medical ‐ LifeSource Acosta Sales and Marketing Company San Jose CA Brea CA http://www.LifeSourceOnline.com http://www.acosta.com Aaron Industries Inc. Actavis Clinton SC Morristown NJ http://www.aaronindustriesinc.com http://www.actavis.us Abbott Diabetes Care Active International, Inc. Alameda CA Pearl River NY http://www.abbottdiabetescare.com http://www.activeinternational.com Abbott Medical Optics, Inc. Aderans Hair Goods Lake Forest CA Beverly Hills CA http://www.amo‐inc.com http://www.reneofparis.com Abbott Nutrition ADFLOW Health Networks Columbus OH Doylestown PA http://www.ross.com http://www.adflownetworks.com Abbott ‐ Pharmaceutical Products Division Adheris, Inc. Abbott Park IL Burlington MA http://www.abbott.com http://www.adheris.com Absolute AR Advance Sales Group, Inc. Fort Worth TX Commerce CA http://www.pdxinc.com http://www.advancesalesgroup.com Accera, Inc. Advanced Beauty, Inc. Broomfield CO Dallas TX http://www.accerapharma.com http://www.bodycology.us Accord Healthcare Advanced Marketing & Sales, Inc. Durham NC Vernon Hills IL http://accord‐healthcare.com http://www.amsrep.com Acon Laboratories Inc. Advanced Vision Research San Diego CA Lake Forest IL http://www.aconlabs.com http://www.theratears.com Associate Member Companies as of October 15, 2012 Advantage Consumer Healthcare LLC Alex Orthopedic, Inc. Pittsburgh PA Grand Prairie TX http://www.advantagechc.com http://www.alexorthopedic.com Advantage Sales and Marketing The Alkalol Company Irvine CA Boston MA http://www.asmnet.com http://www.alkalolcompany.com Adwin USA, Inc., Dba COHBE Allergan Inc. Carson CA Irvine CA http://www.cohbe.com http://www.allergan.com Affinnova Allison Medical Inc.
    [Show full text]
  • American Foundation for Pharmaceutical Education Box: 8
    Ronald Reagan Presidential Library Digital Library Collections This is a PDF of a folder from our textual collections. Collection: Turner, Carlton E.: Files Folder Title: American Foundation for Pharmaceutical Education Box: 8 To see more digitized collections visit: https://reaganlibrary.gov/archives/digital-library To see all Ronald Reagan Presidential Library inventories visit: https://reaganlibrary.gov/document-collection Contact a reference archivist at: [email protected] Citation Guidelines: https://reaganlibrary.gov/citing National Archives Catalogue: https://catalog.archives.gov/ .. i ! f;c~~~ I I ,J I American Foundation For Pharmaceutical Education I OIRECTOF)S RADBURN PLAZA BUILDING 14-25 PLAZA ROAD, FAIR LAWN, N.J. 07410 Ronald J. Brenner. Ph.D. (201) 791-5192 INCORPORATED 1942 Cytogen Corpnr~lion William H. Campbell. Ph .D. March 3, 1986 Unfrersity of Washington Herbert 5. Carlin OFFICERS The New York Hospital Peter G. Tombros. Chaimratt of Board Paul N. Clark Abbott Wboralories Ronald J. Brenner. Ph.D .. Via Clwimum of Board L. Jack R. Cole. Ph.D. Robert Hanson, Treasurer William F. Weigel. Coumel and S(•aetary Uni\·ersity of Ariwna Thomas M. Collins Carlton E. Turner, Ph.D. E. PresitJ,,,u SmithK/i11e Beckman Corpora/ion Richard Faust. Ph.D .. Herbert J. Conrad Deputy Assistant to the President Hoffmann-Lo Roche Inc. for Drug Abuse Policy John W. Culligan American Home Products Corporation The White House Angele C. D"Angelo Washington, DC 20001 St. John's University Robert A . Dube Owens-Illinois Dear Carlton, Frederick M. Eckel 1he University of Nonh Carolina George W. Eckelmann Thanks for your kind note just before the holidays ..
    [Show full text]
  • Discontinued Items Ct
    Discontinued Items ct Smith # Sz Description NDC/UPC Manufacturer 785006 1ct Paliperidone ER Tab 3mg 30ct 30591369330 Actavis/Teva 816686 1ct Irbesartan Tab 75mg 90ct 36233204190 Alembic Pharma 816652 1ct Irbesartan Tab 150mg 500ct 36233204271 Alembic Pharma 816660 1ct Irbesartan Tab 300mg 500ct 36233204371 Alembic Pharma 816678 1ct Irbesartan Tab 300mg 90ct 36233204390 Alembic Pharma 767558 1ct Valsartan Tab 40mg 90ct 36233204490 Alembic Pharma 767574 1ct Valsartan Tab 80mg 500ct 36233204571 Alembic Pharma 860023 1ct Econazole Nitrate Cream 1% 15gm 34778154372 Alvogen, Inc. 860031 1ct Econazole Nitrate Cream 1% 30gm 34778154373 Alvogen, Inc. 689729 1ct BV Pain Rel Caplets XS 2x100ct 34948334120 Basic Drugs 666172 1ct Dulco Gas Max Str Tangy Citrus 18ct 68142102611 Chattem Drug 195115 1ct Halls C Drops Sp/Mint Bag 30’s 31254662742 Dot Foods, Inc. 330019 1ct JJ Sport Tape 1 1/2x10yd 38137007902 Dot Foods, Inc. 381251 1ct Halls Defense Vit C S/Bry 20x9 Loz 31254605091 Dot Foods, Inc. 863753 1ct Fluocinonide Gel .05% 15gm 30713080315 G&W Labs 752238 1ct Aspirin Child Chew 81mg 3x36ct 30536100862 Major/Rugby 211169 1ct Reguloid S/Free Powder 10oz 30536188179 Major/Rugby 251884 1ct Lorazepam Tab .5mg 500ct 30378232105 Mylan Pharma 256982 1ct Lorazepam Tab 1mg 100ct 30378245701 Mylan Pharma 250662 1ct Lorazepam Tab 1mg 1000ct 30378245710 Mylan Pharma 259416 1ct Lorazepam Tab 2mg 100ct 30378277701 Mylan Pharma 246934 1ct Lorazepam Tab 2mg 500ct 30378277705 Mylan Pharma 740175 1ct Finasteride Tab 5mg 90ct 30378503677 Mylan Pharma 542753 1ct Levocetirizine/Dihydr Tab 5mg 300ct 34580259487 Perrigo Pharma 319574 1ct Colocort Enema 60ml 30574202001 Perrigo Pharma 687962 1ct Klor-Con M20 Tab ER 20MEQ 1000ct 36675819010 Sandoz Inc.
    [Show full text]
  • Product Stewardship Financing Models: a Look at the Post-Consumer Pharmaceutical Stewardship Association
    Product Stewardship Financing Models: A Look at the Post-Consumer Pharmaceutical Stewardship Association Type of Brand-owner funded take-back program (mandatory in BC and Manitoba). Program: Pharmaceuticals and natural health products, including prescription drugs, nonprescription Scope: medicines and natural health products such as herbal products, mineral and vitamin supplements (accepted in household quantities). In 1997, the B.C. Waste Management Act – Post Consumer Residual Stewardship, required all Status: brand-owners of pharmaceutical products to be responsible for their products’ end-of-life disposal. Starting in 2000, PCPSA began managing the stewardship plan with the Medications Return Program. The Recycling Regulation (B.C. Reg 449/2004) has now replaced the previous regulation. Overview Unused medications are a health and safety hazard when stored in patients’ homes. They can also damage the natural environment when incorrectly used or disposed of. The Post-Consumer Pharmaceutical Stewardship Association (PCPSA) is a non-profit organization that directly administers the Medications Return Program through funding from pharmaceutical and consumer health products members. PCPSA was established by the industry to comply with British Columbia’s Waste Management Act, a law intended to reduce the environmental and public health risks associated with consumer goods, including leftover medications. The act requires producers to establish a system to safely collect and dispose of the public’s unused medications. PCPSA has been successfully administering the program since 2000 and now represents over 140 pharmaceutical and consumer health products brand-owners (see the final page for a full listing). While these programs are regulated in British Columbia and Manitoba similar programs are run on a voluntary basis in other provinces and territories The program has been extremely successful in gaining the support and participation of community pharmacies.
    [Show full text]
  • Participating Vendor List October 2020
    Participating Vendor List October 2020 Contracted Vendor Additions Contracted Vendor Deletions Accord BioPharma, Inc. ACADIA Pharmaceuticals Inc. Adhezion Biomedical, LLC AdvancePierre Foods, Inc Automated HealthCare Solutions, LLC Allcare, Inc. Balance Vibration Technologies, Inc. Alliance Tech Medical, Inc. CitraPac, Inc. Bon Chef, Inc DuBois Chemicals, Inc. Bryton Corporation Exalt Printing Solutions, LLC Cardinal International Healthcare Information LLC Carter- Hoffmann Corp. Hershey Creamery Company Cosmed USA Kay Kare LLC Dinex International, Inc. Link America, LLC Faxitron Bioptics Merchant Advocate, LLC GE-OEC Medical Systems, Inc. Plastic Film, LLC Medcomflow SDI Labs Inc Medic Vision Imaging Solutions Ltd Sugar Foods Corporation National Recall Alert Center Sunfarm Food Service Pharm3r LLC Syracuse Banana Co., Inc. Sapheneia V. Marchese Inc. Stanley Elevator Company, Inc. Vari Sales Corporation T2 Biosystems Ziehm Imaging Inc Premier, Inc. 10/19/2020 Page 1 NOTE: -Contracted vendors are in plain text. -Vendors who have submitted bids are highlighted in YELLOW. Name Top Parent Name Ownership Stock Symbol Exchange 2G Medical, LLC. 2G Medical, LLC. Private 3 West Medical 3 West Medical Private 3M Company 3M Company Public MMM NYSE 3M Health Information Systems 3M Company Public MMM NYSE 3T Medical Systems LLC 3T Medical Systems LLC Private 410 Medical, Inc 410 Medical, Inc 4WEB Medical, Inc. 4WEB Medical, Inc. Private 6P International LLC 6P International LLC Private 7D Surgical 7D Surgical 8K Miles Software Services / Serj Solutions 8K Miles Software Services / Serj Solutions A M Communications Solutions Inc. A M Communications Solutions Inc. Private A Management Group A Management Group Private A&A Produce Co. A&A Produce Co. A&D Medical A&D Medical Private A&E Enterprises of Louisiana, LLC A&E Enterprises of Louisiana, LLC A&E Medical Corporation A&E Medical Corporation Private A-1 International, Inc.
    [Show full text]
  • Pharma-Manufacturers.Pdf
    List of Pharmaceutical Producers Whose Products May Be Distributed in Contra Costa County Wholesaler Company Name: ______________________________________________________ Phone Number:________________________________________________ Address:_______________________________________________________________________ Email Address:_________________________________________________ City and State:____________________________________ Zip Code:______________________ State/Province/ Box Company Name Address Address 2 Address 3 City Region Zip Code □ 21st Century Healthcare, Inc. 2119 S Wilson St Tempe AZ 85282-2034 □ 3B Global 3030 N. Rocky Point Dr. #150 Tampa Florida 33607 □ 3G Warehouse/Intimore Corp 565 Broadhollow Rd Ste 1 Farmingdale NY 11735 □ 3M Espe Company 3 M Center, Bldg-223 Saint Paul MN 55133-0001 □ 3M Espe Company 2111 Mcgaw Avenue Irvine CA 92614 □ 3M Espe Dental 3350 N Granada Ave Oakdale MN 55128 □ 3M Espe Dental Products 3M Center Bldg 275-2SE-03 St. Paul MN 55144 □ 3M Health Care 22100 Telegraph Road Southfield MI 48034 □ 3M Healthcare 3M Center Building 275-5E-08 Saint Paul MN 55144 □ 3M Personal Care 6023 South Garfield Ave Los Angeles CA 90040 □ 3M-Consumer Health Care 2807 Paysphere Cir Chicago IL 60674 □ 7 Oaks Pharmaceutical Corp. 161 Harry Stanley Dr Easley SC 29640-6619 □ A Better Way Of Life Inc 2935 Stockyard Rd Ste L3 Missoula MT 59808 □ A M Bickford 12318 Big Tree Rd Wales Center NY 14169 □ A&D Engineering 1765 Automation Pkwy San Jose CA 95131 □ A&D Engineering Inc PO Box 31001-1688 Pasadena CA 91110-1688 □ A&D Medical 1756 Automation Parkway San Jose CA 95131 □ A. R. Medicom 1200 55th Ave Montreal, Quebec Canada H8T 3J8 □ Aaa Pharmaceutical Inc 681 Main St Lumberton NJ 08048-5013 □ Aadivighnesh Chem Private Ltd.
    [Show full text]